DOCSLIB.ORG

PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2011) (Rev

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Harmonized Tariff Schedule of the United States (2011) (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2011) (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACEVALTRATE 25161-41-5 ABAFUNGIN 129639-79-8 ACEXAMIC ACID 57-08-9 ABAGOVOMAB 792921-10-9 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABAPERIDONE 183849-43-6 ACITAZANOLAST 114607-46-4 ABARELIX 183552-38-7 ACITEMATE 101197-99-3 ABATACEPT 332348-12-6 ACITRETIN 55079-83-9 ABCIXIMAB 143653-53-6 ACIVICIN 42228-92-2 ABECARNIL 111841-85-1 ACLANTATE 39633-62-0 ABETIMUS 167362-48-3 ACLARUBICIN 57576-44-0 ABIRATERONE 154229-19-3 ACLATONIUM NAPADISILATE 55077-30-0 ABITESARTAN 137882-98-5 ACLIDINIUM BROMIDE 320345-99-1 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURIN 178535-93-8 ACOLBIFENE 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDE 185106-16-5 ACAMPROSATE 77337-76-9 ACOXATRINE 748-44-7 ACAPRAZINE 55485-20-6 ACREOZAST 123548-56-1 ACARBOSE 56180-94-0 ACRIDOREX 47487-22-9 ACEBROCHOL 514-50-1 ACRIFLAVINIUM CHLORIDE 8063-24-9 ACEBURIC ACID 26976-72-7 ACRIHELLIN 67696-82-6 ACEBUTOLOL 37517-30-9 ACRISORCIN 7527-91-5 ACECAINIDE 32795-44-1 ACRIVASTINE 87848-99-5 ACECARBROMAL 77-66-7 ACROCINONIDE 28971-58-6 ACECLIDINE 827-61-2 ACRONINE 7008-42-6 ACECLOFENAC 89796-99-6 ACTAGARDIN ACEDAPSONE 77-46-3 ACTAPLANIN 37305-75-2 ACEDIASULFONE SODIUM 127-60-6 ACTARIT 18699-02-0 ACEDOBEN 556-08-1 ACTINOQUINOL 15301-40-3 ACEFLURANOL 80595-73-9 ACTISOMIDE 96914-39-5 ACEFURTIAMINE 10072-48-7 ACTODIGIN 36983-69-4 ACEFYLLINE CLOFIBROL 70788-27-1 ADAFENOXATE 82168-26-1 ACEFYLLINE PIPERAZINE 18428-63-2 ADALIMUMAB 331731-18-1 ACEGLATONE 642-83-1 ADAMEXINE 54785-02-3 ACEGLUTAMIDE 2490-97-3 ADAPALENE 106685-40-9 ACEMANNAN 110042-95-0 ADAPROLOL 101479-70-3 ACEMETACIN 53164-05-9 ADARGILEUKIN ALFA 250710-65-7 ACENEURAMIC ACID 131-48-6 ADATANSERIN 127266-56-2 ACENOCOUMAROL 152-72-7 ADECATUMUMAB 503605-66-1 ACEPERONE 807-31-8 ADEFOVIR 106941-25-7 ACEPROMAZINE 61-00-7 ADEKALANT 227940-00-3 ACEPROMETAZINE 13461-01-3 ADELMIDROL 1675-66-7 ACEQUINOLINE 42465-20-3 ADEMETIONINE 17176-17-9 ACESULFAME 33665-90-6 ADENOSINE PHOSPHATE 61-19-8 ACETAMINOSALOL 118-57-0 ADERBASIB 791828-58-5 ACETARSOL 97-44-9 ADIBENDAN 100510-33-6 ACETAZOLAMIDE 59-66-5 ADICILLIN 525-94-0 ACETERGAMINE 3031-48-9 ADIMOLOL 78459-19-5 ACETIAMINE 299-89-8 ADINAZOLAM 37115-32-5 ACETIROMATE 2260-08-4 ADIPHENINE 64-95-9 ACETOHEXAMIDE 968-81-0 ADIPIODONE 606-17-7 ACETOHYDROXAMIC ACID 546-88-3 ADIPIPLON 840486-93-3 ACETOPHENAZINE 2751-68-0 ADITEREN 56066-19-4 ACETORPHINE 25333-77-1 ADITOPRIM 56066-63-8 ACETRYPTINE 3551-18-6 ADOPRAZINE 222551-17-9 ACETYLCHOLINE CHLORIDE 60-31-1 ADOSOPINE 88124-26-9 ACETYLCYSTEINE 616-91-1 ADOZELESIN 110314-48-2 ACETYLDIGITOXIN 1111-39-3 ADRAFINIL 63547-13-7 ACETYLLEUCINE 99-15-0 ADRENALONE 99-45-6 ACETYLMETHADOL 509-74-0 ADROGOLIDE 171752-56-0 Harmonized Tariff Schedule of the United States (2011) (Rev. 1) Annotated for Statistical Reporting Purposes 3 AFALANINE 2901-75-9 ALIMADOL 52742-40-2 AFELETECAN 215604-75-4 ALIMEMAZINE 84-96-8 AFELIMOMAB 156227-98-4 ALINASTINE 154541-72-7 AFIMOXIFENE 68392-35-8 ALINIDINE 33178-86-8 AFLIBERCEPT 862111-32-8 ALIPAMIDE 3184-59-6 AFLOQUALONE 56287-74-2 ALIPOGENE TIPARVOVEC 929881-05-0 AFOVIRSEN 151356-08-0 ALISKIREN 173334-57-1 AFUROLOL 65776-67-2 ALITRETINOIN 5300-03-8 AGALSIDASE BETA 104138-64-9 ALIZAPRIDE 59338-93-1 AGALSIDASE ALFA 104138-64-9 ALLETORPHINE 23758-80-7 AGANODINE 86696-87-9 ALLOBARBITAL 52-43-7 AGATOLIMOD 207623-20-9 ALLOCLAMIDE 5486-77-1 AGLEPRISTONE 124478-60-0 ALLOCUPREIDE SODIUM 5965-40-2 AGOMELATINE 138112-76-2 ALLOMETHADIONE 526-35-2 AKLOMIDE 3011-89-0 ALLOPURINOL 315-30-0 ALACEPRIL 74258-86-9 ALLYLESTRENOL 432-60-0 ALACIZUMAB PEGOL 934216-54-3 ALLYLPRODINE 25384-17-2 ALAFOSFALIN 60668-24-8 ALLYLTHIOUREA 109-57-9 ALAGEBRIUM CHLORIDE 341028-37-3 ALMADRATE SULFATE 60239-66-9 ALAMIFOVIR 193681-12-8 ALMAGATE 66827-12-1 ALANINE 56-41-7 ALMAGODRATE 103371-13-8 ALANOSINE 5854-93-3 ALMASILATE 71205-22-6 ALAPROCLATE 60719-82-6 ALMECILLIN 87-09-2 ALATROFLOXACIN 157182-32-6 ALMESTRONE 10448-96-1 ALAZANINE TRICLOFENATE 5779-59-9 ALMINOPROFEN 39718-89-3 ALBACONAZOLE 187949-02-6 ALMITRINE 27469-53-0 ALBENDAZOLE OXIDE 54029-12-8 ALMOKALANT 123955-10-2 ALBENDAZOLE 54965-21-8 ALMOREXANT 871224-64-5 ALBIFYLLINE 107767-55-5 ALMOTRIPTAN 154323-57-6 ALBIGLUTIDE 782500-75-8 ALMOXATONE 84145-89-1 ALBINTERFERON ALFA-2B 472960-22-8 ALMURTIDE 61136-12-7 ALBUTOIN 830-89-7 ALNESPIRONE 138298-79-0 ALCAFTADINE 147084-10-4 ALNIDITAN 152317-89-0 ALCLOFENAC 22131-79-9 ALOGLIPTIN 850649-61-5 ALCLOMETASONE 67452-97-5 ALONACIC 105292-70-4 ALCLOXA 1317-25-5 ALONIMID 2897-83-8 ALCURONIUM CHLORIDE 15180-03-7 ALORACETAM 119610-26-3 ALDESULFONE SODIUM 144-75-2 ALOSETRON 122852-42-0 ALDIOXA 5579-81-7 ALOVUDINE 25526-93-6 ALDOSTERONE 52-39-1 ALOXIPRIN 9014-67-9 ALEFACEPT 222535-22-0 ALOXISTATIN 88321-09-9 ALEGLITAZAR 475479-34-6 ALOZAFONE 65899-72-1 ALEMCINAL 150785-53-8 ALPERTINE 27076-46-6 ALEMTUZUMAB 216503-57-0 ALPHACETYLMETHADOL 17199-58-5 ALENDRONIC ACID 66376-36-1 ALPHAMEPRODINE 468-51-9 ALENTEMOL 112891-97-1 ALPHAMETHADOL 17199-54-1 ALEPLASININ 481629-87-2 ALPHAPRODINE 77-20-3 ALEPRIDE 66564-15-6 ALPIDEM 82626-01-5 ALESTRAMUSTINE 139402-18-9 ALPIROPRIDE 81982-32-3 ALEXIDINE 22573-93-9 ALPRAFENONE 124316-02-5 ALEXITOL SODIUM 66813-51-2 ALPRAZOLAM 28981-97-7 ALFACALCIDOL 41294-56-8 ALPRENOLOL 13655-52-2 ALFADEX 10016-20-3 ALPROSTADIL 745-65-3 ALFADOLONE 14107-37-0 ALRESTATIN 51411-04-2 ALFAPROSTOL 74176-31-1 ALSACTIDE 34765-96-3 ALFATRADIOL 57-91-0 ALTANSERIN 76330-71-7 ALFAXALONE 23930-19-0 ALTAPIZONE 93277-96-4 ALFENTANIL 71195-58-9 ALFERMINOGENE TADENOVEC 473553-86-5 ALTECONAZOLE 93479-96-0 ALFETAMINE 4255-23-6 ALTEPLASE 105857-23-6 ALFIMEPRASE 259074-76-5 ALTINICLINE 179120-92-4 ALFUZOSIN 81403-80-7 ALTIZIDE 5588-16-9 ALGELDRATE 1330-44-5 ALTOQUALINE 121029-11-6 ALGESTONE 595-77-7 ALTRENOGEST 850-52-2 ALGLUCERASE 143003-46-7 ALTRETAMINE 645-05-6 ALTUMOMAB 156586-92-4 ALGLUCOSIDASE ALFA 420784-05-0 ALIBENDOL 26750-81-2 ALUMINIUM CLOFIBRATE 24818-79-9 ALUSULF 61115-28-4 ALICAFORSEN 185229-68-9 ALICONAZOLE 63824-12-4 ALVAMELINE 120241-31-8 ALIFEDRINE 78756-61-3 ALVERINE 150-59-4 ALVESPIMYCIN 467214-20-6 ALIFLURANE 56689-41-9 ALVIMOPAN 156053-89-3 ALILUSEM 144506-11-6 Harmonized Tariff Schedule of the United States (2011) (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 4 ALVIRCEPT SUDOTOX 137487-62-8 AMINOGLUTETHIMIDE 125-84-8 ALVOCIDIB 146426-40-6 AMINOMETRADINE 642-44-4 AMADINONE 30781-27-2 AMINOPHENAZONE 58-15-1 AMAFOLONE 50588-47-1 AMINOPHENAZONE CYCLAMATE 747-30-8 AMANOZINE 537-17-7 AMINOPHYLLINE 317-34-0 AMANTADINE 768-94-5 AMINOPROMAZINE 58-37-7 AMANTANIUM BROMIDE 58158-77-3 AMINOPTERIN SODIUM 58602-66-7 AMANTOCILLIN 10004-67-8 AMINOQUINOL 10023-54-8 AMBAMUSTINE 85754-59-2 AMINOQUINURIDE 3811-56-1 AMBASILIDE 83991-25-7 AMINOREX 2207-50-3 AMBAZONE 539-21-9 AMINOTHIAZOLE 96-50-4 AMBENONIUM CHLORIDE 115-79-7 AMINOXYTRIPHENE 5585-64-8 AMBENOXAN 2455-84-7 AMIODARONE 1951-25-3 AMBICROMIL 58805-38-2 AMIPERONE 1580-71-8 AMBOMYCIN 1402-81-9 AMIPHENAZOLE 490-55-1 AMBRISENTAN 177036-94-1 AMIPIZONE 69635-63-8 AMBROXOL 18683-91-5 AMIPRILOSE 56824-20-5 AMBRUTICIN 58857-02-6 AMIQUINSIN 13425-92-8 AMBUCAINE 119-29-9 AMISOMETRADINE 550-28-7 AMBUCETAMIDE 519-88-0 AMISULPRIDE 71675-85-9 AMBUSIDE 3754-19-6 AMITEROL 54063-25-1 AMCINAFAL 3924-70-7 AMITIVIR 111393-84-1 AMCINAFIDE 7332-27-6 AMITRAZ 33089-61-1 AMCINONIDE 51022-69-6 AMITRIPTYLINE 50-48-6 AMDOXOVIR 145514-04-1 AMITRIPTYLINOXIDE 4317-14-0 AMEBUCORT 83625-35-8 AMIXETRINE 24622-72-8 AMEDALIN 22136-26-1 AMLEXANOX 68302-57-8 AMEDIPLASE 151912-11-7 AMLINTIDE 122384-88-7 AMELOMETASONE 123013-22-9 AMLODIPINE 88150-42-9 AMELTOLIDE 787-93-9 AMOBARBITAL 57-43-2 AMELUBANT 346735-24-8 AMOCARZINE 36590-19-9 AMESERGIDE 121588-75-8 AMODIAQUINE 86-42-0 AMETANTRONE 64862-96-0 AMOGASTRIN 16870-37-4 AMEZEPINE 60575-32-8 AMOLANONE 76-65-3 AMEZINIUM METILSULFATE 30578-37-1 AMOLIMOGENE BEPIPLASMID 870524-46-2 AMFEBUTAMONE 34911-55-2 AMONAFIDE 69408-81-7 AMFECLORAL 5581-35-1 AMOPROXAN 22661-76-3 AMFENAC 51579-82-9 AMOPYROQUINE 550-81-2 AMFEPENTOREX 15686-27-8 AMOROLFINE 78613-35-1 AMFEPRAMONE 90-84-6 AMOSCANATE 26328-53-0 AMFETAMINE 300-62-9 AMOSULALOL 85320-68-9 AMFETAMINIL 17590-01-1 AMOTOSALEN 161262-29-9 AMFLUTIZOLE 82114-19-0 AMOXAPINE 14028-44-5 AMFOMYCIN 1402-82-0 AMOXECAINE 553-65-1 AMFONELIC ACID 15180-02-6 AMOXICILLIN 26787-78-0 AMIBEGRON 121524-08-1 AMOXYDRAMINE CAMSILATE 15350-99-9 AMICARBALIDE 3459-96-9 AMPEROZIDE 75558-90-6 AMICIBONE 23271-63-8 AMPHENIDONE 134-37-2 AMICYCLINE 5874-95-3 AMPHOTALIDE 1673-06-9 AMIDANTEL 49745-00-8 AMPHOTERICIN B 1397-89-3 AMIDAPSONE 3569-77-5 AMPICILLIN 69-53-4 AMIDEFRINE MESILATE 1421-68-7 AMPIROXICAM 99464-64-9 AMIFAMPRIDINE 54-96-6 AMPRENAVIR 161814-49-9 AMIFLAMINE 77518-07-1 AMPROLIUM 121-25-5 AMIFLOVERINE 54063-24-0 AMPYRIMINE 5587-93-9 AMIFLOXACIN 86393-37-5 AMPYZINE 5214-29-9 AMIFOSTINE 20537-88-6 AMQUINATE 17230-85-2 AMIGLUMIDE 119363-62-1 AMRINONE 60719-84-8 AMIKACIN 37517-28-5 AMRUBICIN 110267-81-7 AMIKHELLINE 4439-67-2 AMSACRINE 51264-14-3 AMILORIDE 2609-46-3 AMSILAROTENE 125973-56-0 AMINDOCATE 31386-24-0 AMTOLMETIN GUACIL 87344-06-7 AMINEPTINE 57574-09-1 AMYLMETACRESOL 1300-94-3 AMINITROZOLE 140-40-9 ANACETRAPIB 875446-37-0 AMINOACRIDINE 90-45-9 ANAGESTONE 2740-52-5 AMINOCAPROIC ACID 60-32-2 ANAGRELIDE 68475-42-3 AMINOETHYL NITRATE 646-02-6 ANAKINRA 143090-92-0 Harmonized Tariff Schedule of the United States (2011) (Rev.
Recommended publications
  • Dejong Autman

    Dejong Autman

    King’s Research Portal Document Version Peer reviewed version Link to publication record in King's Research Portal Citation for published version (APA): De Jong, S., Vidler, L., Mokrab, Y., Collier, D. A., & Breen, G. D. (Accepted/In press). Gene-set analysis based on the pharmacological profiles of drugs to identify repurposing opportunities in schizophrenia. Journal of Psychopharmacology. Citing this paper Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections. General rights Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights. •Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research. •You may not further distribute the material or use it for any profit-making activity or commercial gain •You may freely distribute the URL identifying the publication in the Research Portal Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim.
  • The National Drugs List

    The National Drugs List

    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
  • BMC Pharmacology Biomed Central

    BMC Pharmacology Biomed Central

    CORE Metadata, citation and similar papers at core.ac.uk Provided by Springer - Publisher Connector BMC Pharmacology BioMed Central Research article Open Access Pharmacological Properties of DOV 315,090, an ocinaplon metabolite Dmytro Berezhnoy†1, Maria C Gravielle†1, Scott Downing1, Emmanuel Kostakis1, Anthony S Basile2, Phil Skolnick2, Terrell T Gibbs1 and David H Farb*1 Address: 1Laboratory of Molecular Neurobiology, Department of Pharmacology & Experimental Therapeutics, Boston University School of Medicine, 715 Albany St., Boston, MA 02118, USA and 2DOV Pharmaceutical, Inc, 150 Pierce St., Somerset, NJ 08873-4185, USA Email: Dmytro Berezhnoy - [email protected]; Maria C Gravielle - [email protected]; Scott Downing - [email protected]; Emmanuel Kostakis - [email protected]; Anthony S Basile - [email protected]; Phil Skolnick - [email protected]; Terrell T Gibbs - [email protected]; David H Farb* - [email protected] * Corresponding author †Equal contributors Published: 13 June 2008 Received: 20 December 2007 Accepted: 13 June 2008 BMC Pharmacology 2008, 8:11 doi:10.1186/1471-2210-8-11 This article is available from: http://www.biomedcentral.com/1471-2210/8/11 © 2008 Berezhnoy et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Background: Compounds targeting the benzodiazepine binding site of the GABAA-R are widely prescribed for the treatment of anxiety disorders, epilepsy, and insomnia as well as for pre- anesthetic sedation and muscle relaxation. It has been hypothesized that these various pharmacological effects are mediated by different GABAA-R subtypes.
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
  • Immunotherapy in Various Cancers

    Immunotherapy in Various Cancers

    © 2021 JETIR June 2021, Volume 8, Issue 6 www.jetir.org (ISSN-2349-5162) Immunotherapy in various Cancers Nirav Parmar 1st Year MSc Student Department of Biosciences and Bioengineering, IIT- Roorkee India Abstract: Immunotherapy in the metastatic situation has changed the therapeutic landscape for a variety of cancers, including colorectal cancer. Immunotherapy has firmly established itself as a new pillar of cancer treatment in a variety of cancer types, from the metastatic stage to adjuvant and neoadjuvant settings. Immune checkpoint inhibitors have risen to prominence as a treatment option based on a better knowledge of the development of the tumour microenvironment immune cell-cancer cell regulation over time. Immunotherapy has lately appeared as the most potential field of cancer research by increasing effectiveness and reducing side effects, with FDA-approved therapies for more than 10 various tumours and thousands of new clinical studies. Key Words: Immunotherapy, metastasis, immune checkpoint. Introduction: In the late 1800s, William B. Coley, now generally regarded as the founder of immunotherapy, tried to harness the ability of immune system to cure cancer for the first time. Coley began injecting live and attenuated bacteria like Streptococcus pyogenes and Serratia marcescens into over a thousand patients in 1891 in the hopes of causing sepsis and significant immunological and antitumor responses. His bacterium mixture became known as "Coley's toxin" and is the first recorded active cancer immunotherapy treatment [1]. To better understand the processes of new and traditional immunological targets, the relationship between the immune system and tumour cells should be examined. Tumours have developed ways to evade immunological responses.
  • Nicotinic Receptors in Neurodegeneration

    Nicotinic Receptors in Neurodegeneration

    Send Orders of Reprints at [email protected] 298 Current Neuropharmacology, 2013, 11, 298-314 Nicotinic Receptors in Neurodegeneration Inmaculada Posadas, Beatriz López-Hernández and Valentín Ceña* Unidad Asociada Neurodeath. CSIC-Universidad de Castilla-La Mancha, Departamento de Ciencias Médicas. Albacete, Spain and CIBERNED, Instituto de Salud Carlos III, Spain Abstract: Many studies have focused on expanding our knowledge of the structure and diversity of peripheral and central nicotinic receptors. Nicotinic acetylcholine receptors (nAChRs) are members of the Cys-loop superfamily of pentameric ligand-gated ion channels, which include GABA (A and C), serotonin, and glycine receptors. Currently, 9 alpha (2-10) and 3 beta (2-4) subunits have been identified in the central nervous system (CNS), and these subunits assemble to form a variety of functional nAChRs. The pentameric combination of several alpha and beta subunits leads to a great number of nicotinic receptors that vary in their properties, including their sensitivity to nicotine, permeability to calcium and propensity to desensitize. In the CNS, nAChRs play crucial roles in modulating presynaptic, postsynaptic, and extrasynaptic signaling, and have been found to be involved in a complex range of CNS disorders including Alzheimer’s disease (AD), Parkinson’s disease (PD), schizophrenia, Tourette´s syndrome, anxiety, depression and epilepsy. Therefore, there is growing interest in the development of drugs that modulate nAChR functions with optimal benefits and minimal adverse effects. The present review describes the main characteristics of nAChRs in the CNS and focuses on the various compounds that have been tested and are currently in phase I and phase II trials for the treatment of neurodegenerative diseases including PD, AD and age-associated memory and mild cognitive impairment.
  • 1-(4-Amino-Cyclohexyl)

    1-(4-Amino-Cyclohexyl)

    (19) & (11) EP 1 598 339 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 211/04 (2006.01) C07D 211/06 (2006.01) 24.06.2009 Bulletin 2009/26 C07D 235/24 (2006.01) C07D 413/04 (2006.01) C07D 235/26 (2006.01) C07D 401/04 (2006.01) (2006.01) (2006.01) (21) Application number: 05014116.7 C07D 401/06 C07D 403/04 C07D 403/06 (2006.01) A61K 31/44 (2006.01) A61K 31/48 (2006.01) A61K 31/415 (2006.01) (22) Date of filing: 18.04.2002 A61K 31/445 (2006.01) A61P 25/04 (2006.01) (54) 1-(4-AMINO-CYCLOHEXYL)-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS NOCICEPTIN ANALOGS AND ORL1 LIGANDS FOR THE TREATMENT OF PAIN 1-(4-AMINO-CYCLOHEXYL)-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ON DERIVATE UND VERWANDTE VERBINDUNGEN ALS NOCICEPTIN ANALOGE UND ORL1 LIGANDEN ZUR BEHANDLUNG VON SCHMERZ DERIVÉS DE LA 1-(4-AMINO-CYCLOHEXYL)-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ONE ET COMPOSÉS SIMILAIRES POUR L’UTILISATION COMME ANALOGUES DU NOCICEPTIN ET LIGANDES DU ORL1 POUR LE TRAITEMENT DE LA DOULEUR (84) Designated Contracting States: • Victory, Sam AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU Oak Ridge, NC 27310 (US) MC NL PT SE TR • Whitehead, John Designated Extension States: Newtown, PA 18940 (US) AL LT LV MK RO SI (74) Representative: Maiwald, Walter (30) Priority: 18.04.2001 US 284666 P Maiwald Patentanwalts GmbH 18.04.2001 US 284667 P Elisenhof 18.04.2001 US 284668 P Elisenstrasse 3 18.04.2001 US 284669 P 80335 München (DE) (43) Date of publication of application: (56) References cited: 23.11.2005 Bulletin 2005/47 EP-A- 0 636 614 EP-A- 0 990 653 EP-A- 1 142 587 WO-A-00/06545 (62) Document number(s) of the earlier application(s) in WO-A-00/08013 WO-A-01/05770 accordance with Art.
  • Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix

    Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix

    United States International Trade Commission Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix USITC Publication 4208 December 2010 U.S. International Trade Commission COMMISSIONERS Deanna Tanner Okun, Chairman Irving A. Williamson, Vice Chairman Charlotte R. Lane Daniel R. Pearson Shara L. Aranoff Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix Publication 4208 December 2010 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 15, 2010, set forth at the end of this publication, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the United States International Trade Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement changes to the Pharmaceutical Appendix, effective on January 1, 2011. Table 1 International Nonproprietary Name (INN) products proposed for addition to the Pharmaceutical Appendix to the Harmonized Tariff Schedule INN CAS Number Abagovomab 792921-10-9 Aclidinium Bromide 320345-99-1 Aderbasib 791828-58-5 Adipiplon 840486-93-3 Adoprazine 222551-17-9 Afimoxifene 68392-35-8 Aflibercept 862111-32-8 Agatolimod
  • 204569Orig1s000

    204569Orig1s000

    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 204569Orig1s000 MEDICAL REVIEW(S) Cross Discipline Team Leader Review 3. CMC/Device Dr. Khairuzzaman found the drug product portion of the NDA to be acceptable, and without need for phase 4 commitments. Dr. Sapru’s review stated that with the exception of a pending issue concerning the control of potential genotoxic impurity (b) (4) the NDA was approvable in terms of drug substance. Dr. Suarez found that the NDA was acceptable from a biopharmaceutics perspective. The Office of Compliance issuance of an acceptable recommendation for drug substance manufacturing and testing facilities was pending at the time of this review. 4. Nonclinical Pharmacology/Toxicology Dr. Richard Siarey completed the primary nonclinical review, and Dr. Lois Freed completed a supervisory memo. Dr. Siarey’s overall conclusion was that from a nonclinical perspective, approval of the suvorexant NDA was recommended. However, he found evidence that catapelxy was observed in dogs exposed to MK-4305 (suvorexant) near Tmax, although he concluded that additional information could have been gained by studying the drug in an experimental model that has been used for diagnosing cataplexy in dogs. Dr. Siarey suggested that since cataplexy occurred in dogs near Tmax, a time at which if used for insomnia patients would ordinarily be in bed, safety concern for humans was reduced. Dr. Siarey also found that the neurobehavioral assessment in the pre- and post-natal developmental study was not complete, as the passive avoidance tests was performed too early in development, while learning/acquisition tests and retention/memory tests were not conducted.
  • Theophylline-7-Acetic Acid

    Theophylline-7-Acetic Acid

    Theophylline-7-acetic acid sc-237085 Material Safety Data Sheet Hazard Alert Code Key: EXTREME HIGH MODERATE LOW Section 1 - CHEMICAL PRODUCT AND COMPANY IDENTIFICATION PRODUCT NAME Theophylline-7-acetic acid STATEMENT OF HAZARDOUS NATURE CONSIDERED A HAZARDOUS SUBSTANCE ACCORDING TO OSHA 29 CFR 1910.1200. NFPA FLAMMABILITY1 HEALTH2 HAZARD INSTABILITY0 SUPPLIER Santa Cruz Biotechnology, Inc. 2145 Delaware Avenue Santa Cruz, California 95060 800.457.3801 or 831.457.3800 EMERGENCY ChemWatch Within the US & Canada: 877-715-9305 Outside the US & Canada: +800 2436 2255 (1-800-CHEMCALL) or call +613 9573 3112 SYNONYMS C9-H10-N4-O4, "purine-7-acetic acid, 1, 2, 3, 6-tetrahydro-1, 3-dimethyl-2, 6-dioxo-", acefylline, acephylline, 7-(carboxymethyl)theophylline, "1, 2, 3, 6-tetrahydro-1, 3-dimethyl-2, 6-dioxopurine-7-acetic acid", "7-theophyllineacetic acid", "7-theophyllinylacetic acid", alkaloid Section 2 - HAZARDS IDENTIFICATION CHEMWATCH HAZARD RATINGS Min Max Flammability: 1 Toxicity: 2 Body Contact: 2 Min/Nil=0 Low=1 Reactivity: 1 Moderate=2 High=3 Chronic: 2 Extreme=4 1 of 8 CANADIAN WHMIS SYMBOLS EMERGENCY OVERVIEW RISK Harmful if swallowed. Irritating to eyes, respiratory system and skin. POTENTIAL HEALTH EFFECTS ACUTE HEALTH EFFECTS SWALLOWED ! Accidental ingestion of the material may be harmful; animal experiments indicate that ingestion of less than 150 gram may be fatal or may produce serious damage to the health of the individual. ! Xanthine derivatives may produce nausea, vomiting, anorexia, stomach pain, vomiting of blood and diarrhea. Protein in the urine, increased amounts of urine output, and increased excretion of renal tubular cells and red blood cells may also occur.
  • New Contributions in Undergraduate Research

    New Contributions in Undergraduate Research

    PSU McNair Scholars Online Journal Volume 11 Issue 1 Without Borders: Original Contributions Article 6 in Undergraduate Research 2017 Wings Outstretched: New Contributions in Undergraduate Research Follow this and additional works at: https://pdxscholar.library.pdx.edu/mcnair Let us know how access to this document benefits ou.y Recommended Citation (2017) "Wings Outstretched: New Contributions in Undergraduate Research," PSU McNair Scholars Online Journal: Vol. 11: Iss. 1, Article 6. https://doi.org/10.15760/mcnair.2017.01 This open access Full Issue is distributed under the terms of the Creative Commons Attribution-NonCommercial- ShareAlike 4.0 International License (CC BY-NC-SA 4.0). All documents in PDXScholar should meet accessibility standards. If we can make this document more accessible to you, contact our team. Portland State University McNair Research Journal 2017 Without Borders: Original Contributions in Undergraduate Research 2017 Ronald E. McNair Scholars Journal Portland State University 1 About the Program The Portland State University (PSU) Ronald E. McNair Scholars Program at Portland State University works with motivated and talented undergraduates who want to pursue PhDs. It introduces juniors and seniors who are first-generation and low income, and/or members of under-represented groups to academic research and to effective strategies for getting into and graduating from PhD programs. The McNair Scholars Program has academic-year activities and a full-time summer research internship. Scholars take academic and skills-building seminars and workshops during the year, and each scholar works closely with a faculty mentor on original research in the summer. Scholars present their research findings at the McNair Summer Symposium and at other conferences, and are encouraged to publish their papers in the McNair Journal and other scholarly publications.
  • Anti-Infectives Industry Over the Next 5 Years and Beyond

    Anti-Infectives Industry Over the Next 5 Years and Beyond

    Bridging the innovation gap... New Drug Futures: Products that could change the pharma market to 2013 and beyond Over 70 pipeline prospects This new major and insightful 450 page in 8 major therapy areas analysis evaluates, compares and contrasts the are analysed in this report prospects for the development compounds that could revolutionise the pharmaceutical Anti-infectives industry over the next 5 years and beyond. Cardiovascular CNS The report provides: Gastrointestinal Detailed background and market context for Metabolic each therapy area covered: Musculoskeletal Addressable patient population Oncology Current treatments Sales drivers Respiratory Sales breakers Future treatments Market dynamics – winners and losers Key drug launches by 2013 Unique sales forecasts by major product to 2013 Over 70 key products assessed Unique evaluation scores for key areas such as novelty of mechanism, clinical data and competition Critical and detailed appraisal of each product‟s research and development Extensive pipeline listings, putting the profiled products into their competitive context The search – and need – for new products has never been greater and what’s in the development pipeline has never generated more interest. That is why this analysis is so important! GLOBAL PHARMA MARKET IN CONTEXT THE Are there too many prophets of doom ready to write-off the research-based pharma industry in the future? Too few novel There is plenty on which to base such anxiety. The research-based industry products and an must achieve a fair price in the face of greater cost control, while the aggressive generic burden of regulation is setting the bar high for successful product sector are taking introduction.